# Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease

> **NCT04040894** · — · APPROVED_FOR_MARKETING · sponsor: **Amgen**

## Conditions studied

- Thyroid Eye Disease
- Graves' Orbitopathy

## Interventions

- **BIOLOGICAL:** Teprotumumab

## Key facts

- **NCT ID:** NCT04040894
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04040894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04040894, "Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04040894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*